Rise and shine, everyone, another busy day is on the way. And it is getting off to a good start here on the Pharmalot campus, where we have cool breezes and clear blue skies greeting us today. Who could ask for anything more? Actually, we could — it is time to reheat the coffee kettle for another cup of stimulation. Our choice today is almond biscotti, a new choice we procured just last night. Please feel free to join us. Remember, no prescription is required. And now, here are your tidbits. Hope you have a productive and meaningful day, and, as always, please do keep in touch. We have adjusted our settings to accept postcards and telegrams. …
Novo Nordisk’s diabetes blockbuster Ozempic beat Eli Lilly’s older drug Trulicity in a real-world survey of certain U.S. patients, Bloomberg News notes. Medicare patients who took Ozempic were 23% less likely to have a heart attack or stroke or die than people on Trulicity, Novo said in a presentation at the European Association for the Study of Diabetes conference in Vienna. The study followed almost 60,000 people with diabetes and heart disease. Both Ozempic and Trulicity are in the class of GLP-1 drugs that have revolutionized weight-loss treatment. The idea that some are better than others at warding off heart disease is a cornerstone of Novo’s effort to fight off Lilly in the competitive field of obesity and related diseases. Lilly has been taking market share with its newer medicines Mounjaro and Zepbound. Both companies have sought to compare their current blockbusters with their rivals’ older drugs in a race to produce data that could convince doctors to prescribe one drug over another.
Advertisement